{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:04:44Z","timestamp":1779980684198,"version":"3.53.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jvs.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:26:30Z","timestamp":1770855990000},"page":"1637-1648.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0897-4611","authenticated-orcid":false,"given":"Jason S.","family":"Chwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-6391","authenticated-orcid":false,"given":"Alexander T.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4448-678X","authenticated-orcid":false,"given":"Forest","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7564-1843","authenticated-orcid":false,"given":"William","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-5266","authenticated-orcid":false,"given":"Zhiwen J.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukgu M.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-9175","authenticated-orcid":false,"given":"David G.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-9482","authenticated-orcid":false,"given":"Tze-Woei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2026.02.006_bib1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jvs.2026.02.006_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvs.2026.02.006_bib3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jvs.2026.02.006_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.jvs.2026.02.006_bib5","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvs.2026.02.006_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.jvs.2026.02.006_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvs.2026.02.006_bib8","doi-asserted-by":"crossref","first-page":"18531","DOI":"10.1002\/cam4.6455","article-title":"Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: a retrospective cohort study","volume":"12","author":"Zhu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jvs.2026.02.006_bib9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1055\/s-0041-1733927","article-title":"Arterial thrombosis in cancer patients: an update","volume":"47","author":"Franchini","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jvs.2026.02.006_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.mayocp.2020.05.045","article-title":"Incidence and risk of various types of arterial thromboembolism in patients with cancer","volume":"96","author":"Wang","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jvs.2026.02.006_bib11","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2026.02.006_bib12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jvs.2026.02.006_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2023.105322","article-title":"Implementation of a commercial federated network of electronic health record data to enable sponsor-initiated clinical trials at an academic medical center","volume":"182","author":"Campion","year":"2024","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.jvs.2026.02.006_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jvs.2026.02.006_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.jvs.2026.02.006_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jvs.2026.02.006_bib17","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2026.02.006_bib18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1001\/jama.2021.2126","article-title":"Lower extremity peripheral artery disease without chronic limb-threatening ischemia: a review","volume":"325","author":"Polonsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2026.02.006_bib19","doi-asserted-by":"crossref","DOI":"10.2196\/18542","article-title":"Model-based algorithms for detecting peripheral artery disease using administrative data from an electronic health record data system: algorithm development study","volume":"8","author":"Weissler","year":"2020","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.jvs.2026.02.006_bib20","article-title":"Evaluation of the ICD-10 system in coding revascularisation procedures in patients with peripheral arterial disease in England: a retrospective cohort study using national administrative and clinical databases","volume":"55","author":"Birmpili","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jvs.2026.02.006_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1358863X251328671","article-title":"A scoping review of electronic phenotyping methodologies used to identify peripheral artery disease in observational studies","volume":"30","author":"Appah-Sampong","year":"2025","journal-title":"Vasc Med"},{"key":"10.1016\/j.jvs.2026.02.006_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.124.011467","article-title":"Validation of ICD-10 codes to distinguish between claudication and chronic limb-threatening ischemia in patients undergoing peripheral vascular intervention using medicare-matched registry data","volume":"18","author":"Bose","year":"2025","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jvs.2026.02.006_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007332","article-title":"Frequency of care and mortality following an incident diagnosis of peripheral artery disease in the inpatient or outpatient setting: the ARIC (atherosclerosis risk in communities) study","volume":"7","author":"Kalbaugh","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jvs.2026.02.006_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0801","article-title":"Foot and ankle care by podiatrists and amputations in patients with diabetes and kidney failure","volume":"7","author":"Tan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvs.2026.02.006_bib25","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.2337\/dc25-0292","article-title":"Differential effect of GLP-1 receptor agonists and SGLT2 inhibitors on lower-extremity amputation outcomes in type 2 diabetes: a nationwide retrospective cohort study","volume":"48","author":"Hong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jvs.2026.02.006_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112982","article-title":"Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease","volume":"230","author":"Hong","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jvs.2026.02.006_bib28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jvs.2023.01.200","article-title":"Updated estimates for the burden of chronic limb-threatening ischemia in the Medicare population","volume":"77","author":"Kwong","year":"2023","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.006_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jvscit.2022.10.003","article-title":"Deriving international classification of diseases, 9th and 10th revision, codes for identifying and following up patients with diabetic lower extremity ulcers","volume":"8","author":"Fowler","year":"2022","journal-title":"J Vasc Surg Cases Innov Tech"},{"key":"10.1016\/j.jvs.2026.02.006_bib30","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2026.02.006_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvs.2026.02.006_bib32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jvs.2021.03.058","article-title":"A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer","volume":"74","author":"Govsyeyev","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.006_bib33","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jvs.2015.06.223","article-title":"Frequency of cancer in patients operated on for acute peripheral arterial thrombosis and the impact on prognosis","volume":"62","author":"Nicolajsen","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.006_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2026.02.006_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2026.02.006_bib36","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3390\/ijms25052502","article-title":"Association between immune checkpoint inhibitors and atherosclerotic cardiovascular disease risk: another brick in the Wall","volume":"25","author":"Piras","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jvs.2026.02.006_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","article-title":"Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review","volume":"79","author":"Vuong","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jvs.2026.02.006_bib38","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jvs.2026.02.006_bib39","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2026.02.006_bib40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jvs.2026.02.006_bib41","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2026.02.006_bib42","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvs.2026.02.006_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvs.2026.02.006_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cancers12010067","article-title":"Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients","volume":"12","author":"Nichetti","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvs.2026.02.006_bib45","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jvs.2026.02.006_bib46","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jvs.2026.02.006_bib47","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvs.2026.02.006_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.yjmcc.2008.10.028","article-title":"Contributions of PD-1\/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis","volume":"46","author":"Lee","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jvs.2026.02.006_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvs330","article-title":"CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-\/-) mice","volume":"97","author":"Ma","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jvs.2026.02.006_bib50","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jvs.2026.02.006_bib51","doi-asserted-by":"crossref","first-page":"e007307","DOI":"10.1136\/jitc-2023-007307","article-title":"Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer","volume":"11","author":"Drobni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jvs.2026.02.006_bib52","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521426001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521426001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T14:25:03Z","timestamp":1779978303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521426001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0741521426001023"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2026.02.006","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Vascular Surgery. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}